|Bid||7.22 x 800|
|Ask||7.22 x 1200|
|Day's range||7.05 - 7.35|
|52-week range||1.34 - 12.68|
|Beta (5Y monthly)||1.89|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||19.33|
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.